- Home
- MIY vs NGNE Comparison
MIY vs NGNE Comparison
Compare MIY & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIY
- NGNE
- Stock Information
- Founded
- MIY 1992
- NGNE 2003
- Country
- MIY United States
- NGNE United States
- Employees
- MIY N/A
- NGNE N/A
- Industry
- MIY Investment Bankers/Brokers/Service
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- MIY Finance
- NGNE Health Care
- Exchange
- MIY Nasdaq
- NGNE Nasdaq
- Market Cap
- MIY 321.2M
- NGNE 325.3M
- IPO Year
- MIY N/A
- NGNE N/A
- Fundamental
- Price
- MIY $11.17
- NGNE $18.48
- Analyst Decision
- MIY
- NGNE Strong Buy
- Analyst Count
- MIY 0
- NGNE 7
- Target Price
- MIY N/A
- NGNE $41.86
- AVG Volume (30 Days)
- MIY 56.8K
- NGNE 110.1K
- Earning Date
- MIY 01-01-0001
- NGNE 08-11-2025
- Dividend Yield
- MIY 3.98%
- NGNE N/A
- EPS Growth
- MIY N/A
- NGNE N/A
- EPS
- MIY N/A
- NGNE N/A
- Revenue
- MIY N/A
- NGNE N/A
- Revenue This Year
- MIY N/A
- NGNE N/A
- Revenue Next Year
- MIY N/A
- NGNE N/A
- P/E Ratio
- MIY N/A
- NGNE N/A
- Revenue Growth
- MIY N/A
- NGNE N/A
- 52 Week Low
- MIY $9.45
- NGNE $6.88
- 52 Week High
- MIY $11.70
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- MIY 58.77
- NGNE 35.93
- Support Level
- MIY $11.07
- NGNE $19.59
- Resistance Level
- MIY $11.24
- NGNE $20.46
- Average True Range (ATR)
- MIY 0.11
- NGNE 1.23
- MACD
- MIY -0.00
- NGNE -0.20
- Stochastic Oscillator
- MIY 73.53
- NGNE 13.37
About MIY Blackrock MuniYield Michigan Quality Fund Inc.
Blackrock Muniyield Michigan Quality Fund Inc is a closed end fund. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.